| | Beyond anti-VEGF: Investigative drugs, approaches abound
| | Drugs are under development and in clinical trials that can complement anti-vascular endothelial growth factor drugs (VEGF) and attack age-related macular degeneration in ways that differ from the anti-VEGF approach. If these prove successful, many more patients can benefit from therapy for AMD. | |  |
|
|
| | | Anti-VEGF therapy is on the horizon for APROP
| BLOCK-ROP study will add to knowledge of safety, efficacy of drug in treating aggressive disease
| | Ophthalmology Times | | Anti-angiogenic therapy for aggressive posterior retinopathy of prematurity (ROP) may be a feasible therapy for the children with this form of ROP, which develops in profoundly immature neonates. The BLOCK-ROP study, which will begin in the second quarter of 2008, will add to the limited knowledge of the safety and efficacy of an anti-vascular endothelial growth factor drug in treating posterior ROP. |
| | |
| Antioxidants key to prevent blindness
| | Ophthalmology Times | | It has just been discovered by researchers at Brigham Young University and Weill Medical College of Cornell University that two processes in the retina, which in combination contribute to age-related macular degeneration, can be disrupted by antioxidants. |
| | | UV rays don't just damage skin
| | Ophthalmology Times | | Prevent Blindness has dedicated May as UV Awareness Month in an effort to educate the public on the best way to protect their eyes. |
| | Risk of glaucoma increases with diabetes, study supports
| | Ophthalmology Times | |
It appears that diabetic retinopathy is not the only eye disease associated with diabetes, according to a study, which found that women with diabetes have about a 70% increased risk of developing the most common form of glaucoma—primary-open angle glaucoma—compared with women without diabetes. |
| |
| 
